A randoMized phAse II trIal of fulvestraNt wiTh or Without Ribociclib After Progression on AntI-estrogeN Therapy Plus Cyclin-dependent Kinase 4/6 Inhibition in Patients With Unresectable or Metastatic Hormone Receptor Positive, HER2 Negative Breast Cancer (MAINTAIN Trial)
Phase of Trial: Phase II
Latest Information Update: 18 Dec 2017
At a glance
- Drugs Ribociclib (Primary) ; Fulvestrant
- Indications Breast cancer; Male breast cancer
- Focus Therapeutic Use
- Acronyms MAINTAIN
- 02 Jun 2017 Trial design of the study presented at the 53rd Annual Meeting of the American Society of Clinical Oncology.
- 17 Mar 2016 Status changed from not yet recruiting to recruiting, according to ClinicalTrials.gov record.
- 18 Dec 2015 New trial record